July 22, 2016

July 22, 2016

NCI names clinical investigator team leadership award winners
The Cancer Letter – July 2016 Issue  (Page 9)
Frederick Locke, of Moffitt Cancer Center and Research Institute

Final results for Phase III trial of CPX-351 reveal reduced mortality risk in AML
Targeted Oncology – July 21
“CPX-351 should be considered standard first-line treatment for older patients with high-risk AML,” the principal investigator for the study, Jeffrey E. Lancet, MD, senior member and chief of the Leukemia/Myelodysplasia Program at Moffitt Cancer Center, said when presenting the data at ASCO.

Combining PROs And Clinical Data To Benefit Cancer Patients & Researchers
Clinical Leader – July 21
Cancer researchers will combine patient-reported data shared by PatientsLikeMe members with the molecular and clinical data provided by patients treated at two National Cancer Institute-designated cancer centers: Moffitt Cancer Center and The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. 

Molecular Targets Remain Elusive in Most Sarcomas
OncLive – July 21
Andrew S. Brohl, MD, is a medical oncologist at Moffitt Cancer Center, specializing in sarcomas. His research focuses on the study of sarcoma genomics and the application of genomic data for personalized cancer therapy.

Dr. Strosberg on Pasireotide for Neuroendocrine Tumors
OncLive – July 20
Jonathan R. Strosberg, MD, associate professor at H. Lee Moffitt Cancer Center, discusses pasireotide as a potential treatment for patients with neuroendocrine tumors (NETs).

Immune checkpoint inhibitors show promise in brain tumors
Healio – July 20
The promise of immune checkpoint inhibitors in systemic cancers such as melanoma, non-small-cell lung cancer and breast cancer has prompted researchers to start examining the potential for these immunotherapies in the management of primary and metastatic brain tumors, according to Peter A. Forsyth, MD, FACP, MA, of the H. Lee Moffitt Cancer Center & Research Institute at the University of Southern Florida.

Immunotherapy: What is the Role in Lymphoid Cancers?
OncLive – July 20
I am Dr. Ian Flinn. I’m the director of the Sarah Cannon Center for Blood Cancer in Nashville, Tennessee. Joining me today are Dr. Krishna Komanduri, professor of medicine and director of the Adult Stem Cell Transplant Program at the Sylvester Comprehensive Cancer Center at the University of Miami; Dr. Andre Goy, the chairman and executive director at the John Theurer Cancer Center located in Hackensack, New Jersey; and Dr. Frederick Locke, assistant member and director of the Immune Cellular Therapy and Research Program at the Moffitt Cancer Center in Tampa, Florida.

Tampa executive takes key post at a Jacksonville biopharma
Tampa Bay Business Journal – July 20
“Immuno-oncology is just beginning to bloom in science, with new drugs coming onto the market based on the fact that we understand the immune system better than in the past,” Bonfiglio said. One of the clinical trial sites is at Moffitt Cancer Center in Tampa and TapImmune is talking with Moffitt about a potential second trial. 

Dean sees bright present and future for USF’s medical school
Tampa Bay Times – July 20
He also wants to build on the partnerships with Tampa General, All Children's, Moffitt Cancer Center, and Bayfront Health St. Petersburg.

Carlton: What Stacy would want you to know
Tampa Bay Times – July 19
Here is what Stacy Frank would want me to tell you: That, according to a spokesman for the Moffitt Cancer Center, non-smokers are a growing percentage of lung cancer cases —15 to 20 percent and women in particular. 

New firstline treatment for older patients with secondary AML
Oncology Times – July 2016
“This is a significant advancement in the field for a group of patients who do not respond well to any therapy in general, and is a solid platform for future drug development. We may have a new standard of care for older adults with secondary AML,” Jeffrey Lancet, MD, Senior Member and Professor at Moffitt Cancer Center, Tampa, Fla., told Oncology Times.

Securing flights to Havana opens doors for Tampa Bay region
Tampa Bay Times – July 15
Pinellas County interests are well represented in the letter campaign, including St. Petersburg Mayor Rick Kriseman and Eckerd College. They share the boilerplate language with Hillsborough interests such as Port Tampa Bay and Moffitt Cancer Center.

Moffitt Cancer Center seeking smokers for e-cigarette study
Florida Courier – July 15
The National Institutes of Health has awarded Moffitt Cancer Center a research grant to study changes in traditional cigarette and e-cigarette use over time among individuals who are currently using both products.

Editorial: Freebies to docs should not affect prescriptions for patients
Tampa Bay Times – July 15
Two others in the for-profit HCA chain were close behind, Tampa Community Hospital and Memorial Hospital of Tampa. Moffitt Cancer Center posted the lowest rate in Tampa Bay, but still reported 60 percent of affiliated doctors accepting payments. None of these figures should inspire confidence.

Moffitt will use grant to provide hundreds of free mammograms
Tampa Bay Business Journal – July 15
Moffitt Cancer Center will be able to provide 400 to 450 free mammograms through a grant from the National Breast Cancer Foundation.

Young Adult Cancer Treatment Programs Fill Need
Hospitals and Health Network – July 15
Quantify the need: While diagnoses in this age group constitute about 5 percent of all malignancies, the demand for services may vary from hospital to hospital. When leaders at Moffitt Cancer Center in Tampa, Fla., were looking to develop a program, they determined that AYA patients constituted 12 percent of all new patients and were filling roughly one out of 10 beds, according to the 2014 JNCCN article on creating AYA programs.

###

Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.